Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

Balance Sheet

v3.8.0.1
Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 8,736 $ 5,007
Prepaid expenses and other 727 215
Total current assets 9,463 5,222
Furniture and equipment, net of accumulated depreciation of $14 and $6, respectively 22 23
Intangible assets 11,148 11,148
Total assets 20,633 16,393
Current liabilities:    
Accounts payable and accrued expenses 1,089 1,069
Convertible notes payable 0 276
Warranty liability 743 0
Total current liabilities 1,832 1,345
Long-term deferred compensation – related party 150 88
Total liabilities 1,982 1,433
Commitments and contingencies (Note 7) 0 0
Stockholders’ equity    
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding 0 0
Common stock, $0.001 par value; 75,000,000 shares authorized, 20,822,214 issued outstanding at September 30, 2017 and 12,164,852 issued and outstanding at December 31, 2016 21 12
Additional paid-in capital 29,925 19,623
Accumulated deficit (11,295) (4,675)
Total stockholders’ equity 18,651 14,960
Total liabilities and stockholders’ equity $ 20,633 $ 16,393

Source